BENNETT C FRANK 4
4 · IONIS PHARMACEUTICALS INC · Filed Sep 4, 2025
Insider Transaction Report
Form 4
BENNETT C FRANK
EVP, Chief Scientific Officer
Transactions
- Sale
Common Stock
2025-09-02$49.14/sh−5,000$245,700→ 88,679 total - Exercise/Conversion
Common Stock
2025-09-03$61.50/sh−12,891$792,797→ 88,679 total - Sale
Common Stock
2025-09-03$60.62/sh−33,909$2,055,564→ 101,570 total - Exercise/Conversion
Common Stock
2025-09-03$53.77/sh+46,800$2,516,436→ 135,479 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-09-03−46,800→ 0 totalExercise: $53.77From: 2020-01-02Exp: 2026-01-01→ Common Stock (46,800 underlying)
Footnotes (3)
- [F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 13, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.25 to $61.24 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.26 to $61.995 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (e) on this Form 4.